BioSpace News Archive

Zerion Pharma A/S announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers.

Lotus Clinical Research announced it has entered into a strategic partnership with Trialogics to strengthen their existing relationship and expand Lotus’ use of Trialogics’ clinical trial software offerings.

Azafaros B.V. announced that the first patient has been enrolled into its Phase 2 RAINBOW study.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Executive Director of the Company’s Board of Directors.

Obvius Robotics, Inc., a medical device company that has developed an innovative technology platform for performing percutaneous access, announced the successful completion of its first human cases.

Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, reminded stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST.

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.

Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to sell its Respiratory Health (RH) business to SunMed Group Holdings, LLC (SunMed).

Protalix BioTherapeutics, Inc. today announced it will host an in-person KOL breakfast in New York on Tuesday, June 27, 2023 at 8:00 a.m. Eastern Daylight Time (EDT), with presentations beginning at 8:30 a.m. EDT.

SunMed today announced it has entered into a definitive agreement with Avanos Medical, Inc. (NYSE: AVNS) (“Avanos”), under which SunMed will acquire Avanos’ respiratory health business, including the BALLARD*, MICROCUFF* and endOclear® product lines.